With an Impact Factor of 4.400, Frontiers in Pharmacology is the 1st most cited open-access journal in Pharmacology & Pharmacy
This year, 256 journals are listed in the category of Pharmacology & Pharmacy in the 2016 edition of the Journal Citation Reports (JCR), of which 20 are open-access (OA).
The Impact Factor (IF) is measured each year and reported in the JCR by Clarivate Analytics (formerly known as Thomson Reuters), along with citations and other metrics of journal impact. The IF of a journal is the average number of citations received last year to articles published in the previous two years – and is universally regarded as a metric of journal quality. The total number of citations captures how much research is built on the papers published in a journal and is therefore a measure of influence of a journal on a field. As such, the 2016-JCR analysis is based on citations in 2016 to articles published in 2014 and 2015.
Our analysis shows that the quality, impact and influence of Frontiers journals are steadily growing. With an Impact Factor of 4.400, Frontiers in Pharmacology is the 1st most cited open-access journal in the category of Pharmacology & Pharmacy, with a total of 2,222 citations in 2016 to 505 articles published in 2014 and 2015 (Figure 1).
In summary, Frontiers in Pharmacology:
- Is the 1st most-cited open-access journal, with 2,222 citations.
- Ranks at the 87th percentile of Journal Impact Factors in the category of Pharmacology & Pharmacy.
Top 10 most cited open-access journals in Pharmacology & Pharmacy
Figure 1. Total number of citations in 2016 to articles published in 2014 and 2015, for the top 10 most cited open-access journals in Pharmacology & Pharmacy. Bar plot shows Frontiers in Pharmacology (in red) ranks 1st most cited over 20 open-access journals indexed. The results are based on the 2016 Journal Citation Reports, released in 2017 by Clarivate Analytics.
Scientific Excellence at Scale
Frontiers has become one of the largest open-access publishers in the world and is leading many of the technological innovations in Open Science. We engineered our Collaborative Peer Review with a review mandate focused on enhancing article quality by means of rigorous and constructive feedback from expert reviewers, quick and direct interactions between authors, reviewers and the editor. We enable their work with our unique review forum platform, and we introduced transparency and accountability by acknowledging reviewers and editors on the published articles.
With journals listed across 20 academic categories in the 2016-JCR, Frontiers journals rank in the top percentiles of Impact Factors and total citations. This confirms the rapidly growing success and influence of the Frontiers Open Science model, that consistently delivers scientific excellence at scale.
All of this is only possible with a stellar editorial board of researchers. Frontiers congratulates Field Chief Editor Théophile Godfraind and all Specialty Chief Editors, as well as the diligent work of the Associate and Review Editors and the Frontiers Journal Management team for this outstanding achievement.
Frontiers in Pharmacology Editorial Board
(see full board here)
Théophile Godfraind, Frontiers Media SA | Field Chief Editor, Pharmacology
Martin Michel, Johannes Gutenberg University of Mainz | Specialty Chief Editor, Cardiovascular and Smooth Muscle Pharmacology
Jeffrey Atkinson, Université de Lorraine | Specialty Chief Editor, Cardiovascular and Smooth Muscle Pharmacology
Eliot Ohlstein, Drexel University | Specialty Chief Editor, Cardiovascular and Smooth Muscle Pharmacology
Jaime Kapitulnik, The Hebrew University of Jerusalem | Specialty Chief Editor, Drug Metabolism and Transport
Michael Heinrich, University College London (UCL) | Specialty Chief Editor, Ethnopharmacology
Yung-Chi Cheng, Yale University | Specialty Chief Editor, Ethnopharmacology
Salvatore Salomone, University of Catania | Specialty Chief Editor, Experimental Pharmacology and Drug Discovery
Angelo Izzo, University of Naples Federico II | Specialty Chief Editor, Gastrointestinal and Hepatic Pharmacology
Paola Patrignani, University of Chieti-Pescara | Specialty Chief Editor, Inflammation Pharmacology
George Christ, University of Virginia | Specialty Chief Editor, Integrative and Regenerative Pharmacology
Alex Chen, University of Pittsburgh Medical Center | Specialty Chief Editor, Integrative and Regenerative Pharmacology
Nicholas Barnes, University of Birmingham | Specialty Chief Editor, Neuropharmacology
Anne Zajicek, National Institutes of Health | Specialty Chief Editor, Obstetric and Pediatric Pharmacology
Jeffrey Barrett, Children’s Hospital of Philadelphia | Specialty Chief Editor, Obstetric and Pediatric Pharmacology
Dominique Dubois, Free University of Brussels | Specialty Chief Editor, Pharmaceutical Medicine and Outcomes Research
Ulrich Zanger, Dr. Margarete Fischer-Bosch Institut für Klinische Pharmakologie (IKP) | Specialty Chief Editor, Pharmacogenetics and Pharmacogenomics
Olivier Feron, Université Catholique de Louvain | Specialty Chief Editor, Pharmacology of Anti-Cancer Drugs
Philippe Lory, Centre national de la recherche scientifique (CNRS) | Specialty Chief Editor, Pharmacology of Ion Channels and Channelopathies
Diana Conte Camerino, University of Bari Aldo Moro | Specialty Chief Editor, Pharmacology of Ion Channels and Channelopathies
Ursula Gundert-Remy, Bundesinstitut für Risikobewertung | Specialty Chief Editor, Predictive Toxicology
Paolo Montuschi, Universita Cattolica del Sacro Cuore | Specialty Chief Editor, Respiratory Pharmacology
Alastair Stewart, University of Melbourne | Specialty Chief Editor, Translational Pharmacology
Read more about Frontiers journals